Pembrolizumab gets European Commission approval as front line therapy for high-PDL-1 NSCLC with no ALK/EGFR mutation https://t.co/q5uapCkcQw

Pembrolizumab gets European Commission approval as front line therapy for high-PDL-1 NSCLC with no ALK/EGFR mutation https://t.co/q5uapCkcQw

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/826816132376100865
via IFTTT